scholarly journals Chronic Hepatitis C Screening, Evaluation, and Treatment Update in the Age of Direct-Acting Antivirals

2018 ◽  
Vol 66 (6) ◽  
pp. 302-309 ◽  
Author(s):  
Miranda Surjadi

Globally, hepatitis C virus (HCV), the cause of one of the most common infectious diseases, infects approximately 4 million to 5 million Americans with approximately half of infected individuals undiagnosed. Some workplaces screen employees for HCV exposure and other bloodborne pathogens (BBP) after needlestick injuries, but it is not well known whether employers screen employees for HCV without an occupational exposure. New guidelines from the Centers for Disease Control and Prevention (CDC) recommend that all individuals born between 1945 and 1965 should be screened for HCV regardless of risk; this provides an opportunity at the worksite for HCV outreach to employees, dependents, and retirees. To understand this recommendation, the management of HCV in the age of direct-acting antivirals (DAAs) should be reviewed. Now that new DAA treatment can cure HCV, occupational health nurses should identify potential HCV-positive individuals at the worksite via HCV education, screening, testing, and, if positive, linking to specialists for treatment.

PLoS ONE ◽  
2020 ◽  
Vol 15 (3) ◽  
pp. e0229994
Author(s):  
Sheng Feng Lin ◽  
Shui-Yi Tung ◽  
Kuo-Liang Wei ◽  
Chien-Hung Chen ◽  
Tsung-Hui Hu ◽  
...  

2015 ◽  
Vol 156 (21) ◽  
pp. 841-848
Author(s):  
Gábor Horváth ◽  
Tünde Halász ◽  
Mihály Makara ◽  
Béla Hunyady

Chronic hepatitis C, without treatment, can cause liver cirrhosis, liver failure and liver cancer. The availability of new oral direct acting antivirals, such as the protease inhibitors simeprevir, asunaprevir and paritaprevir, the NS5A inhibitors daclatasvir, ledipasvir, and ombitasvir, the polymerase inhibitors Sofosbuvir and dasabuvir have resulted an enormous progress in the treatment of chronic hepatitis C, leading to >90% sustained viral response rates. Even the hard-to-treat or previously treatment ineligible patients can be cured with the combination of these drugs. Furthermore the treatment duration is much shorter, and the side effects are minimal. Today, treatment of all hepatitis C virus infected patients is recommended, and the best choices are the interferon-free options. Eradication of hepatitis C virus has become realistic, however, appropriate screening programs are mandatory to achieve this goal. Orv. Hetil., 2015, 156(21), 841–848.


2019 ◽  
Vol 09 (10) ◽  
pp. 193-201
Author(s):  
Dimitri Hatrydt Kouamé ◽  
Stanislas Adjéka Doffou ◽  
Henriette Kissi Anzouan-Kacou ◽  
Yannick Mfupa Tchana ◽  
Aboubakar Demba Bangoura ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document